Education
About Us
Working with TipRanks
Follow Us
Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
4527 Stock Chart & Stats
¥2560.00
-¥51.00(-1.80%)
At close: 4:00 PM EST
¥2560.00
-¥51.00(-1.80%)
Day’s Range― - ―
52-Week Range¥1,964.50 - ¥2,703.00
Previous CloseN/A
Volume733.70K
Average Volume (3M)643.03K
Market Cap
¥583.65B
Enterprise Value¥523.80B
Total Cash (Recent Filing)¥75.84B
Total Debt (Recent Filing)¥48.88B
Price to Earnings (P/E)16.5
Beta0.45
Next Earnings
May 19, 2026EPS Estimate
39.08Next Dividend Ex-DateN/A
Dividend Yield1.53%
Share Statistics
EPS (TTM)47.03
Shares Outstanding236,178,310
10 Day Avg. Volume564,110
30 Day Avg. Volume643,026
Financial Highlights & Ratios
PEG Ratio43.69
Price to Book (P/B)1.96
Price to Sales (P/S)1.65
P/FCF Ratio18.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,790.00Price Target Upside8.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins & Revenue GrowthConsistent revenue gains and high margins indicate durable demand and pricing power across Rohto’s product portfolio. Gross margin 54.88% and net margin 10.05% support long-term cash generation and reinvestment capacity, helping the company withstand competitive pressure.
Strong Balance SheetLow leverage (debt/equity 0.19) and a strong equity ratio (61.64%) give Rohto flexibility to fund capex, M&A, or weather downturns without heavy refinancing. ROE of 11.92% reflects efficient capital deployment that supports sustainable returns and strategic optionality.
Solid Cash GenerationRobust cash generation — FCF growth 9.9%, operating cash to net income 1.19, FCF to net income 0.90 — underpins repeatable funding for R&D, marketing, and shareholder returns. Reliable free cash flow reduces reliance on external financing and supports medium-term stability.
Bears Say
Product Concentration RiskConcentration in OTC eye-care and personal-care products creates revenue concentration risk. Market share shifts, changing consumer preferences, or retail channel disruption could disproportionately affect sales and slow durable growth if new categories or geographies underperform.
International Execution RiskInternational expansion is cited as a growth driver but segment-level details are limited, underscoring execution and translation risks. Scaling via local subsidiaries and partners exposes the company to distribution complexity, incremental investment needs, and FX volatility over months.
Operating Margin PressureEBIT margin fell to 12.46%, suggesting rising costs or an adverse product mix. If this trend persists, operating profitability could be pressured, reducing free cash flow conversion and constraining reinvestment, dividend capacity, or pricing flexibility over the medium term.
Rohto Pharmaceutical Co News
4527 FAQ
What was Rohto Pharmaceutical Co Ltd’s price range in the past 12 months?
Rohto Pharmaceutical Co Ltd lowest stock price was ¥1964.50 and its highest was ¥2703.00 in the past 12 months.
What is Rohto Pharmaceutical Co Ltd’s market cap?
Rohto Pharmaceutical Co Ltd’s market cap is ¥583.65B.
When is Rohto Pharmaceutical Co Ltd’s upcoming earnings report date?
Rohto Pharmaceutical Co Ltd’s upcoming earnings report date is May 19, 2026 which is in 90 days.
How were Rohto Pharmaceutical Co Ltd’s earnings last quarter?
Rohto Pharmaceutical Co Ltd released its earnings results on Feb 12, 2026. The company reported ¥47.03 earnings per share for the quarter, beating the consensus estimate of ¥44.108 by ¥2.922.
Is Rohto Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Rohto Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Rohto Pharmaceutical Co Ltd pay dividends?
Rohto Pharmaceutical Co Ltd pays a Semiannually dividend of ¥22 which represents an annual dividend yield of 1.53%. See more information on Rohto Pharmaceutical Co Ltd dividends here
What is Rohto Pharmaceutical Co Ltd’s EPS estimate?
Rohto Pharmaceutical Co Ltd’s EPS estimate is 39.08.
How many shares outstanding does Rohto Pharmaceutical Co Ltd have?
Rohto Pharmaceutical Co Ltd has 236,178,310 shares outstanding.
What happened to Rohto Pharmaceutical Co Ltd’s price movement after its last earnings report?
Rohto Pharmaceutical Co Ltd reported an EPS of ¥47.03 in its last earnings report, beating expectations of ¥44.108. Following the earnings report the stock price went up 0.774%.
Which hedge fund is a major shareholder of Rohto Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4527
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical Co., Ltd. is a prominent Japanese pharmaceutical and consumer healthcare company, known for its innovative products in the fields of ocular health, dermatology, and over-the-counter (OTC) pharmaceuticals. Founded in 1899, Rohto operates in multiple sectors, including pharmaceuticals, healthcare, and cosmetics, focusing on the development and distribution of a wide range of products such as eye drops, skincare products, and dietary supplements. The company is recognized for its commitment to research and development, continually introducing new products to meet consumer needs across various markets.
4527 Stock 12 Month Forecast
Average Price Target
¥2,790.00
▲(8.98% Upside)
Technical Analysis
Options Prices
Currently, No data available
---